Is diabetes becoming the have’s and have not’s

While the toy makers play with their toys and the drug companies battle with payors, an interesting dynamic seems to be developing that’s worth exploring. Has diabetes become a case of the have’s and have nots. Has scale become so critical that it by itself trumps other concerns? Will this stifle innovation as companies grapple with increasing demands for lower prices? Can they successfully navigate the treacherous waters of satisfying the demands of stakeholders while battling with payors over formulary position, discounts and rebates?

Although no one talks about it much whoever has the most patients wins the . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

This entry was posted in Email Alerts. Bookmark the permalink.